Growing Demand for Advanced Dilated Cardiomyopathy Therapeutics Market - Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020
About Dilated Cardiomyopathy Therapeutics Market
Dilated cardiomyopathy is an important cause of heart failure and is one of the leading indications for heart transplantation across the globe. It is characterized by the enlargement of ventricular chamber along with systolic dysfunction. Dilated cardiomyopathy can develop at any age but it is more common among people aged between 20 years and 60 years. According to American Society for Clinical Investigation about 25% - 50% of the total dilated cardiomyopathy cases are genetically caused, owing to mutation in genes encoding for cytoskeleton, contractile, or other proteins in myocardial cells.
The global dilated cardiomyopathy therapeutics market is studied in this report from three perspectives: by drug class, by pipelined products and by geography. Dilated cardiomyopathy therapeutics market by drug class encompasses aldosterone antagonists, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs) and beta-blockers. A detailed market analysis and forecast for each of these segments have been provided in this study, in terms of market revenue (USD million) for the period 2012 to 2020. The report also provides the compounded annual growth rate (CAGR %) for each of these segments for the forecast period from 2014 to 2020, considering 2012 and 2013 as base years. Geographic regions analyzed for this market include North America, Europe, Asia Pacific and Rest of the World. The North American market comprises the United States and Canada. The European market includes countries such as the U.K., Germany, Italy, and Spain that majorly contribute towards the growth of this region. Similarly, the Asia Pacific market primarily considers India, China, Japan, Singapore, and Australia, along with other smaller markets.
Get Sample Copy of this report @ http://www.marketresearchreports.biz/sample/sample/269810
The market overview section of the report demonstrates the major factors determining the market dynamics such as drivers, restraints and opportunities that influence the current as well as future status of this industry. The market overview section of the report also includes qualitative and quantitative analysis of the competitive landscape covering market share analysis by key players.
The study also suggests a list of recommendations which would be useful for existing and future market players in decision making for business growth. Pipeline analysis (Phase I and Phase II) for dilated cardiomyopathy therapeutics market has also been covered in the report. The report concludes with the company profiles section, which illustrates key information about the major players in this market such as company overview, financial overview, product portfolio, business strategies and recent developments. Key players profiled in the report include Array BioPharma, Inc., AstraZeneca plc, Celladon Corporation, GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Novartis International AG, Pfizer, Inc., Teva Pharmaceutical Industries Ltd, and Vericel Corporation.
View Report @ http://www.marketresearchreports.biz/analysis/269810
The global dilated cardiomyopathy therapeutics market is segmented into the following categories:
Dilated cardiomyopathy therapeutics market, by drug class
Aldosterone antagonists
Angiotensin-converting enzyme (ACE) inhibitors
Angiotensin II receptor blockers (ARBs)
Beta-blockers
Dilated cardiomyopathy therapeutics market, by pipeline drugs
ARRY-797
ixCELL-DCM
MYDICAR
OR-1
CAP-1002
Dilated cardiomyopathy therapeutics market, by geography
North America
Europe
Asia Pacific
Rest of the World (RoW)
Dilated cardiomyopathy is an important cause of heart failure and is one of the leading indications for heart transplantation across the globe. It is characterized by the enlargement of ventricular chamber along with systolic dysfunction. Dilated cardiomyopathy can develop at any age but it is more common among people aged between 20 years and 60 years. According to American Society for Clinical Investigation about 25% - 50% of the total dilated cardiomyopathy cases are genetically caused, owing to mutation in genes encoding for cytoskeleton, contractile, or other proteins in myocardial cells.
The global dilated cardiomyopathy therapeutics market is studied in this report from three perspectives: by drug class, by pipelined products and by geography. Dilated cardiomyopathy therapeutics market by drug class encompasses aldosterone antagonists, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs) and beta-blockers. A detailed market analysis and forecast for each of these segments have been provided in this study, in terms of market revenue (USD million) for the period 2012 to 2020. The report also provides the compounded annual growth rate (CAGR %) for each of these segments for the forecast period from 2014 to 2020, considering 2012 and 2013 as base years. Geographic regions analyzed for this market include North America, Europe, Asia Pacific and Rest of the World. The North American market comprises the United States and Canada. The European market includes countries such as the U.K., Germany, Italy, and Spain that majorly contribute towards the growth of this region. Similarly, the Asia Pacific market primarily considers India, China, Japan, Singapore, and Australia, along with other smaller markets.
Get Sample Copy of this report @ http://www.marketresearchreports.biz/sample/sample/269810
The market overview section of the report demonstrates the major factors determining the market dynamics such as drivers, restraints and opportunities that influence the current as well as future status of this industry. The market overview section of the report also includes qualitative and quantitative analysis of the competitive landscape covering market share analysis by key players.
The study also suggests a list of recommendations which would be useful for existing and future market players in decision making for business growth. Pipeline analysis (Phase I and Phase II) for dilated cardiomyopathy therapeutics market has also been covered in the report. The report concludes with the company profiles section, which illustrates key information about the major players in this market such as company overview, financial overview, product portfolio, business strategies and recent developments. Key players profiled in the report include Array BioPharma, Inc., AstraZeneca plc, Celladon Corporation, GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Novartis International AG, Pfizer, Inc., Teva Pharmaceutical Industries Ltd, and Vericel Corporation.
View Report @ http://www.marketresearchreports.biz/analysis/269810
The global dilated cardiomyopathy therapeutics market is segmented into the following categories:
Dilated cardiomyopathy therapeutics market, by drug class
Aldosterone antagonists
Angiotensin-converting enzyme (ACE) inhibitors
Angiotensin II receptor blockers (ARBs)
Beta-blockers
Dilated cardiomyopathy therapeutics market, by pipeline drugs
ARRY-797
ixCELL-DCM
MYDICAR
OR-1
CAP-1002
Dilated cardiomyopathy therapeutics market, by geography
North America
Europe
Asia Pacific
Rest of the World (RoW)
Table of Contents
Chapter 1 Introduction
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology
1.3.1 Secondary Research
1.3.2 Primary Research
1.4 List of Abbreviations
1.5 Assumptions and Stipulations
Chapter 2 Executive Summary
2.1 Market Snapshot: Global Dilated Cardiomyopathy Therapeutics Market (2013 & 2020)
2.2 Comparative Analysis: Global Dilated Cardiomyopathy Therapeutics Market Revenue, by Geography, 2013 & 2020 (Value %)
Chapter 3 Global Dilated Cardiomyopathy Therapeutics Market Overview
3.1 Market Definition and Overview
3.1.1 Classification of Cardiomyopathies
3.1.2 Market Drivers
3.1.2.1
Increasing number of heart failure cases worldwide will lead to rise in
demand for effective medications, thereby driving market growth
3.1.3 Market Restraints
3.1.3.1 Side effects associated with DCM drugs could restrain market growth
3.1.3.2 Enhanced relief from use of devices without any side effects will restrain the dilated cardiomyopathy drugs market
3.1.4 Promising gene and stem cell therapies for DCM treatment may hamper the DCM drugs market growth
3.1.5 Market Opportunities
3.1.7 Increasing genericization of DCM drugs
3.2 Market Attractiveness Analysis: Global Dilated Cardiomyopathy Therapeutics Market, by Geography, 2013
3.3 Epidemiology (Prevalence, Cause, Mortality Rate)
3.4 Epidemiology Studies on Dilated Cardiomyopathy
3.5 Causes and Mortality
3.6 Event Impact Analysis
3.7 Competitive Landscape, by Key Players, 2013 (Value %)
3.7.1 Market share by key players, 2013 (Value %)
Chapter 4 Global Dilated Cardiomyopathy Therapeutics Market, by Drug Class
4.1 Introduction
4.1.1 Global Dilated Cardiomyopathy Therapeutics Market Revenue, by Drug Class 2012 – 2020 (USD Million)
4.2 Aldosterone Antagonists
4.2.1 Global Aldosterone Antagonists Market Revenue, 2012 - 2020 (USD Million)
4.3 Angiotensin-Converting Enzymes (ACE) Inhibitors
4.3.1 Global Angiotensin-Converting Enzyme (ACE) Inhibitors Market Revenue, 2012 - 2020 (USD Million)
4.4 Angiotensin II Receptor Blocker (ARBs)
4.4.1 Global Angiotensin II Receptor Blockers (ARBs) Market Revenue, 2012 - 2020 (USD Million)
4.5 Beta-Blockers
4.5.1 Global Beta-Blockers Market Revenue, 2012 - 2020 (USD Million)
About us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save time
and money for our clients. We are a one stop solution for all your
research needs, our main offerings are syndicated research reports,
custom research, subscription access and consulting services. We serve
all sizes and types of companies spanning across various industries.
Contact
Mr. Nachiket
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-621-2074
E: sales@marketresearchreports.biz
Comments
Post a Comment